Supernus Pharmaceuticals
- Market cap
- 2.51B
- P/E (TTM)i
- -22.42
- P/Bi
- 2.43
- EPSi
- -0.68
- Div yieldi
- 0.00%
- 52W posi
- 13%
Anonymous reader poll. Unscientific, not investment advice.
Valuation each multiple against its own 5-year range
Vs. peers Drug Manufacturers - Specialty & Generic
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Supernus Pharmaceuticals (SUPN) | 2.51B | -22.42 | 2.43 | 0.00% |
| Takeda Pharmaceutical (TAK) | 58.68B | -55.67 | 1.23 | 3.26% |
| Teva Pharmaceutical Industries (TEVA) | 45.70B | 65.30 | 5.89 | 0.00% |
| Haleon (HLN) | 39.67B | 18.87 | 1.83 | 2.11% |
| Zoetis (ZTS) | 29.57B | 11.67 | 9.39 | 2.88% |
| United Therapeutics (UTHR) | 23.38B | 19.53 | 3.65 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 11.6% below Morningstar's fair value estimate.
Fair value
Supernus Pharmaceuticals Inc earns a 3-star quantitative star rating, illustrating our stance that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 11% discount to our quantitative fair value estimate of $48.06 per share; however, caution is warranted due to this estimate's high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.
We need more explanatory data to elaborate on this stock's star rating. We strive to explain the factors driving every rating we assign; however, this is not yet possible for a small fraction of our coverage universe.
Economic moat
The company's quantitative economic moat rating of none suggests any excess returns could erode quickly as competition arrives. However, its financial health score is strong, suggesting that the company should be well positioned to weather tough times.
By Quantitative Equity Report
Quote time 2026-10-08 04:02:46 · For reference only, not investment advice and not tailored to your situation.